Helping you detect, treat and manage arthritis

Good news in Ontario!

Girl in flight mid airTofacitinib (Xeljanz®) for the treatment of rheumatoid arthritis approved in Ontario.

As of June 17th, tofacitinib (Xeljanz®) for the treatment of moderate to severe rheumatoid arthritis has been listed for coverage on Ontario’s drug formulary.

Tofacitinib is an oral targeted small molecule medicine (TSMM) that was issued a Notice of Compliance (NOC) from Health Canada on April 17, 2014. Tofacitinib in combination with methotrexate (MTX), is indicated for reducing the signs and symptoms of RA, in adult patients with moderately to severely active RA who have had an inadequate response to MTX. In cases of intolerance to MTX, physicians may consider the use of tofacitinib as monotherapy.

Click here to view the most up-to-date version of ACE's Report Card on provincial formulary reimbursement listings for biologic response modifiers.